Emergent BioSolutions secures $62.4 million contract for botulism antitoxin

Published 23/06/2025, 13:22
Emergent BioSolutions secures $62.4 million contract for botulism antitoxin

GAITHERSBURG, Md. - Emergent BioSolutions Inc. (NYSE: EBS), a biotech company with a market capitalization of approximately $338 million, has been awarded a $62.4 million contract modification from the Administration for Strategic Preparedness and Response (ASPR), a division of the U.S. Department of Health and Human Services, the company announced Monday. According to InvestingPro analysis, the company appears undervalued based on its Fair Value metrics, with analysts projecting net income growth this year.

The modification extends an existing 10-year contract for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)], which is used to treat symptomatic botulism following suspected or confirmed exposure to botulinum neurotoxin in adults and pediatric patients. The company maintains a strong financial position with a current ratio of 6.32, indicating robust liquidity to support its operations. For deeper insights into Emergent's financial health and growth prospects, consider exploring the comprehensive Pro Research Report available on InvestingPro.

"The ongoing commitment by the U.S. government to stockpile BAT® reinforces the importance of Emergent's medical countermeasures," said Paul Williams, senior vice president at Emergent BioSolutions.

BAT® is a mixture of immune globulin fragments indicated for treating botulism after exposure to botulinum neurotoxin serotypes A through G. The effectiveness of the product is based on studies conducted in animal models of botulism, according to the company.

The antitoxin may cause severe hypersensitivity reactions, including anaphylaxis and delayed allergic reactions. Common adverse reactions reported in clinical trials included headache, nausea, pruritus, and urticaria.

The contract supports the U.S. government's efforts to maintain stockpiles of medical countermeasures against potential biological threats. The types and quantities of products maintained in government stockpiles depend on the population requiring protection, available products, and government resources and priorities.

Emergent BioSolutions has been developing protective solutions for health threats including smallpox, mpox, botulism, Ebola, anthrax, and opioid overdose emergencies for over 25 years, according to information provided in the company's press release statement. The company generated $965.4 million in revenue over the last twelve months, with a notable free cash flow yield that InvestingPro analysts identify as particularly strong among its peers.

In other recent news, Emergent BioSolutions reported a substantial increase in net income for Q1 2025, with a 656% rise to $68 million, despite a decline in total revenues to $222 million. The company highlighted improvements in adjusted EBITDA margin, which increased by 1,300 basis points to 35%. Emergent BioSolutions reaffirmed its full-year 2025 revenue guidance, projecting between $750 million and $850 million, with expectations for revenue to be weighted towards the second half of the year. The company's strategic initiatives, including divestitures and restructuring efforts, have reduced operating expenses by 32%. Additionally, Emergent BioSolutions announced its inclusion in the Russell 3000 Index, effective after the market close on June 27, 2025. This development is part of the annual reconstitution of Russell U.S. stock indexes. The company also secured a three-year agreement valued at approximately $65 million with the province of Ontario to supply its NARCAN treatment. Analyst firm H.C. Wainwright has inquired about the company's international sales potential and manufacturing capabilities, suggesting potential growth opportunities.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.